Keyphrases
Hematology
75%
Spinal Cord
75%
Flow Cytometric
75%
Monoclonal Antibody
75%
Hyper-CVAD
75%
Upper Part
75%
Primary Refractory
75%
CCR4
75%
Cerebrospinal Fluid
75%
Gemcitabine
75%
Cisplatin
75%
CRLF2
75%
Ruxolitinib
75%
Mogamulizumab
75%
Angioimmunoblastic T-cell Lymphoma
75%
Rituximab Plus Cyclophosphamide
75%
Circulating Tumor DNA (ctDNA)
75%
Lymphoma
75%
Early Molecular Response
50%
JAK Inhibition
45%
Elderly Patients
30%
Second-generation Tyrosine Kinase Inhibitors
24%
Dasatinib
24%
BCR-ABL1
24%
Vascular Adverse Events
24%
Warm Autoimmune Hemolytic Anemia
24%
T-lymphoblasts
18%
Early Disease Progression
18%
Monotherapy
15%
In Cancer
15%
Tumor Immunity
15%
Autoimmunity
15%
Partial Remission
15%
Cancer Patients
15%
Salvage Therapy
15%
Toxicity Profile
15%
Cytotoxic Activity
15%
Relapsed or Refractory
15%
Treatment Response
15%
Regulatory T Cells
15%
Older Patients
15%
Immunochemotherapy
15%
Puma
15%
Salvage Chemotherapy
15%
TNFRSF10B
15%
Early Progression
10%
Cerebrospinal Fluid Analysis
7%
CD79B mutation
7%
Mis-splicing
5%
FAB Classification
5%
Medicine and Dentistry
Myeloid Leukemia
75%
Angioimmunoblastic T-Cell Lymphoma
75%
Gemcitabine
75%
COVID-19
75%
Monoclonal Antibody
75%
Magnetic Resonance Imaging
75%
Dexamethasone
75%
Cisplatin
75%
Evans Syndrome
75%
Mogamulizumab
75%
Cerebrospinal Fluid
75%
Hematology
75%
Circulating Tumor DNA
75%
Monotherapy
30%
Anemia
30%
Prednisolone
30%
Follicular Lymphoma International Prognostic Index
30%
Elderly Patient
30%
Dasatinib
18%
Nilotinib
18%
Cytotoxicity
15%
Autoimmune Disease
15%
Hemolytic Anemia
15%
Salvage Therapy
15%
Weakness
15%
Treatment Response
15%
Clinician
15%
Coombs Test
15%
Bilirubin
15%
Autoimmunity
15%
Lactate Dehydrogenase
15%
Emergency Department
15%
Disease
15%
Malignant Neoplasm
15%
Regulatory T Cell
15%
T Lymphoblast
12%
Cerebrospinal Fluid Analysis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisolone
100%
Disease
85%
First-Line Chemotherapy
75%
Coronavirinae
75%
Rituximab
75%
Vincristine
75%
Circulating Tumor DNA
75%
Doxorubicin
75%
Autoimmune Hemolytic Anemia
75%
Follicular Lymphoma
75%
Ruxolitinib
75%
Cyclophosphamide
75%
Mogamulizumab
75%
Overall Survival
53%
Vaccination Policy
37%
Lactate Dehydrogenase
33%
Anemia
24%
Survival Rate
21%
Dasatinib
18%
Puma
15%
Hemolytic Anemia
12%
Autoimmune Disease
12%
Monotherapy
12%
Weakness
12%
Bilirubin
12%
Clinical Feature
10%